Enliven Therapeutics (ELVN) Preferred Dividend Payments (2020)

Enliven Therapeutics (ELVN) reported Preferred Dividend Payments of -$42000.0 for Q3 2020, down 200.0% sequentially from $42000.0 in Q2 2020.

Enliven Therapeutics (ELVN) Preferred Dividend Payments (2020) Analysis & Trends

Enliven Therapeutics (ELVN) has 1 years of Preferred Dividend Payments data on file, last reported at -$42000.0 in Q3 2020.

For the quarter ending Q3 2020, Preferred Dividend Payments changed N/A year-over-year to -$42000.0; the trailing twelve-month figure through Dec 2020 stood at $7.9 million (changed N/A YoY), and the FY2021 full-year result was $7.9 million, up 0.53% from the prior year.
Preferred Dividend Payments eased to -$42000.0 in Q3 2020, from $42000.0 in the prior quarter.
In the past five years, Preferred Dividend Payments ranged from a high of $7.9 million in Q1 2020 to a low of -$42000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Pref Dividends (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Enliven Therapeutics	3.22 Bn	3.22 Bn	-	-

Download Data